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Human papillomavirus (HPV) vaccination of girls in Germany. 
Results of the cross-sectional KiGGS Wave 2 study and trends
Abstract
Since 2007, the Standing Committee on Vaccination (STIKO) has recommended that all girls receive vaccinations against 
the human papillomavirus (HPV) in order to reduce the disease burden of cervical cancer. Persistent infections with 
high-risk HPV subtypes increase a woman’s risk of developing cancer. In the second wave of the German Health Interview 
and Examination Survey for Children and Adolescents (KiGGS Wave 2, 2014-2017), 42% of 2,958 11- to 17-year-old girls 
reported that they had received at least one HPV vaccination, and 31.4% reported a full HPV vaccination. 45.3% of 14- to 
17-year-old girls reported a complete series of HPV vaccinations. Compared to the figures reported in KiGGS Wave 1 five
years ago, HPV vaccination coverage has therefore remained stable. A vaccination coverage below 50% in girls is too
low to exploit the potential of HPV vaccination to reduce cervical cancer rates in Germany.
 HUMAN PAPILLOMAVIRUS · HPV · VACCINATION COVERAGE · TREND · HEALTH MONITORING · KIGGS
Introduction
The human papillomavirus (HPV) is sexually transmitted. 
Without vaccination, over two thirds of all women will con-
tract HPV during the course of their lives [1]. HPV is sub-
divided into high and low risk types. While high risk types 
can lead to cancer (carcinoma), low risk types are known 
to cause genital warts. Types 16 and 18 are the most impor-
tant high risk types that play a critical role in the develop-
ment of cervical carcinoma and cause around 70% of all 
cancers of the cervix uteri globally. 
Factors such as a high virus burden and the carcino-
genicity of a specific virus type further increase the risk of 
cancer. Smoking or an HIV infection increase the risk of 
cancer as well. In most cases, however, an HPV infection 
is cleared without further consequences. The infection 
persists only in about one in ten women for one to two 
years and increases the risk of developing cancer [2]. In 
2014, around 4,540 women were diagnosed with cervical 
cancer in Germany and around 1,540 women died of the 
disease [3]. Over 50,000 women annually are estimated to 
undergo cervical surgery (conisation) to treat HPV-related 
precancerous stages [4]. 
Since 2007, the Standing Committee on Vaccination 
(STIKO) has recommended HPV vaccination for all girls 
as a means of reducing the burden of cervical cancer. Until 
2014, a series of three vaccinations was generally recom-
mended for 12- to 17-year-old girls. In August 2014, the 
STIKO lowered the recommended age for vaccination of 
girls to 9- to 14-years and advised two instead of three vac-
cinations for this age group for full immunisation [5]. 
Correction notice: A more recent version of the article is available at DOI 10.17886/RKI-GBE-2018-102.2
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rates and representa tiveness in issue 1/2018 of the Journal 
of Health Monitor ing  [7, 8].
HPV vaccination coverage was surveyed in KiGGS 
Wave 2 through the answers of 11- to 17-year-old girls to a 
written questionnaire. It contained the question: ‘Have you 
been vaccinated against human papillomavirus (HPV) to 
protect yourself from cervical cancer?’ Respondents answer-
ing ‘yes’ were asked how many vaccinations they had 
received (‘How many HPV vaccinations have you received 
so far?’) and how old they had been when they received 
their initial vaccination (‘At what age were you first vacci-
nated against HPV?’). 
The analyses are based on data from 2,958 girls aged 
11 to 17 with valid information on HPV vaccination. The pro-
portion of missing values on HPV vaccination in the group 
of 11- to 12-year-old girls is high (20.3%) compared with the 
group of 13- to 17-year-old girls (10.6%). The analyses on 
the completed series of HPV vaccinations is based on the 
data collected from 2,916 girls (98.6%) because 42 girls did 
not provide answers to the respective subquestions. Results 
are presented as prevalences (frequencies) for at least one 
vaccination and for the completed vaccination series accord-
ing to current STIKO recommendations. A completed series 
of vaccinations is defined as two vaccinations if started until 
the age of 14 years or three vaccinations if started at 15 years 
or older. The analysis did not consider whether there was a 
minimum interval between vaccinations of six months 
between the two vaccinations (or five months, according to 
current recommendations). The tables show prevalences 
stratified according to age, residence in East or West 
German federal states and socio economic status (SES) [9]. 
To analyse trends, the information on HPV vaccinations 
Catch-up vaccinations are recommended up to the age of 
17 years [6].
The second wave of the German Health Interview and 
Examination Survey for Children and Adolescents (KiGGS 
Wave 2, 2014-2017) now provides data on HPV vaccination 
coverage based on a population-based representative sam-
ple. These data complement the calculation of vaccination 
coverage conducted by the Robert Koch Institute (RKI) in 
cooperation with the Associations of Statutory Health 
Insurance Physicians (ASHIPs) which is based on the anal-
ysis of health insurance claims data (ASHIP vaccination 
monitoring project) and permit the inclusion of privately 
insured girls as well as an analysis of further indicators for 
differences in vaccination uptake. A comparison with data 
collected five years ago in KiGGS Wave 1 allows for a trend 
analysis in HPV vaccination coverage and their determi-
nants.
Indicator
KiGGS is part of the health monitoring system at the RKI 
and includes repeated cross-sectional surveys of children 
and adolescents aged 0 to 17 years (KiGGS cross-section-
al study) that are representative for Germany. The KiGGS 
baseline study (2003-2006) was conducted as an exami-
nation and interview survey, the first follow-up study (KiGGS 
Wave 1, 2009-2012) as a telephone-based interview survey 
and KiGGS Wave 2 (2014-2017) as an examination and 
interview survey. A detailed description of the methodolo-
gy used in KiGGS Wave 2 can be found in New data for 
action. Data collection for KiGGS Wave 2 has been com-
pleted in issue S3/2017 as well as in KiGGS Wave 2 
cross-sectional study – participant acquisition, response 
KiGGS Wave 2 
Second follow-up to the German Health 
Interview and Examination Survey for Children 
and Adolescents 
Data owner: Robert Koch Institute 
Aim: Providing reliable information on health 
status, health-related behaviour, living condi-
tions, protective and risk factors, and health 
care among children, adolescents and young 
adults living in Germany, with the possibility 
of trend and longitudinal analyses 
Study design: Combined cross-sectional and 
cohort study 
Cross-sectional study in KiGGS Wave 2
Age range: 0 -17 years
Population: Children and adolescents with 
permanent residence in Germany
Sampling: Samples from official residency 
registries - randomly selected children and  
adolescents from the 167 cities and municipal-
ities covered by the KiGGS baseline study
Sample size: 15,023 participants 
KiGGS cohort study in KiGGS Wave 2
Age range: 10 -31 years
Sampling: Re-invitation of everyone who took 
part in the KiGGS baseline study and who 
was willing to participate in a follow-up 
Sample size: 10,853 participants 
KiGGS survey waves
▶  KiGGS baseline study (2003-2006),  
examination and interview survey
▶  KiGGS Wave 1 (2009-2012),  
interview survey
▶  KiGGS Wave 2 (2014-2017),  
examination and interview survey
More information is available at 
www.kiggs-studie.de/english
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that respondents self-reported in KiGGS Wave 1 were re- 
calculated following the current STIKO recommendations 
to provide an identical indicator, with the exception of the 
different surveying method (telephone interview vs. written 
questionnaire). Due to the high number of non-respon dents 
among girls less than 14 years of age, trends were cal culated 
limited to 14- to 17-year-old girls, in line with the approach 
chosen to assess KiGGS Wave 1 results [10]. 
The calculations were carried out using a weighting fac-
tor that corrects deviations within the sample from the 
population structure with regard to regional structure 
(rural/urban area), age (in years), gender, federal state (as 
of 31 December 2015), German citizenship (as of 31 Decem-
ber 2014) and the parents’ level of education (Microcensus 
2013 [11]). P-values to demonstrate temporal trends relative 
to KiGGS Wave 1 were based on age-standardised preva-
lences (as of 31 December 2015). This article considers 
prevalences with 95% confidence intervals (95% CI). Preva-
lences are estimates and their precision can be assessed 
through the use of confidence intervals - wide confidence 
intervals indicating a greater statistical uncertainty in the 
results. A statistically significant difference between groups 
is assumed if the corresponding p-value is less than 0.05 
under consideration of weighting and survey design.
Results and discussion
In KiGGS Wave 2, 42.0% of 11- to 17-year-old girls reported 
having received at least one HPV vaccination. The propor-
tion of girls who have received at least one HPV vaccination 
increases with age. Whereas in the group of 11- to 13-year-
old girls, 20.6% had received at least one vaccination, 
this proportion rises to 55.5% among 14- to 17-year-olds. 
Less than one third of 11- to 17-year-old girls has received 
the complete vaccination series. The proportion of girls with 
complete HPV vaccination also increases with age. Only 
9.3% of 11- to 13-year-old girls, but 45.3% of 14- to 17-year-
old girls have received a complete HPV vaccination series 
(Table 1). Figure 1 contains a stratification by single year of 
age. There are significant differences between girls who live 
in East and West German federal states. Whereas the vac-
cination coverage of 11- to 17-year-old girls in the Eastern 
German federal states is 55.6%, a considerably lower pro-
portion of girls in Western Germany has received the com-
plete HPV vaccination series (40.0%) (Table 1). Socio e-
conomic status did not influence HPV coverage.
Compared to the girls interviewed by telephone five 
years ago for KiGGS Wave 1, there are no apparent differ-
ences in vaccination coverage for 14- to 17-year-old girls. 
The proportion of fully vaccinated adolescent girls was 
43.7% in KiGGS Wave 1 and therefore only slightly lower 
than the currently surveyed prevalences (45.3%) (Figure 1). 
The slight rise in the proportion of fully vaccinated younger 
girls might already indicate a tendency towards earlier vac-
cination, which would be in line with the STIKO recommen-
dation of August 2014 to lower the age of vaccination to 
9- to 14-year-old girls [5]. Whereas in KiGGS Wave 1, the 
median age at initial vaccination for 12- to 17-year-old girls 
was 14 years and 2 months, the median age of the 12- to 
17-year old girls surveyed in KiGGS Wave 2 for their first 
HPV vaccination was 13 years and 9 months and therefore 
5 months earlier than in KiGGS Wave 1 (data not shown).
When comparing the HPV vaccination coverage sur-
veyed in KiGGS Wave 2 between 2014 and 2017 with the 
vaccination coverage calculated for 15-year-old girls in 2015 
45.3% of 14- to 17-year-old 
girls have received a 
complete series of HPV 
vaccinations.
Vaccination coverage of girls 
in East German federal 
states is significantly higher 
than in the West German 
federal states.
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based on the ASHIP vaccination monitoring project [12], a 
higher proportion of girls in KiGGS Wave 2 (48.7% of 
15-year-old girls) have received a complete series of HPV 
vaccination than seen in the ASHIP vaccination monitor-
ing project data among girls of that age (31.3 %). The rel-
ative difference between East and West Germany is similar 
in both surveys. Both studies apply current criteria for a 
complete series of HPV vaccination: two vaccinations are 
considered sufficient if the first dose is administered before 
the age of 14 years. However, only ASHIP data takes into 
account an important additional condition for the two-dose 
schedule: a minimum of six months between the first and 
second vaccination dose is required. Consideration of this 
requirement might have contributed to the lower vaccina-
tion coverage reported by the ASHIP vaccination monitor-
ing project. Further possible explanations could be recall 
bias in self-reporting on vaccinations as well as providing 
socially desired answers. Moreover, it can be assumed that 
At least on HPV vaccination dose Complete HPV vaccination series*
% (95 % CI) % (95% CI)
Girls (total) 42.0 (39.1-45.1) Girls (total) 31.4 (28.9-33.9)
Age group Age group
11-13 Years 20.6 (17.7-23.8) 11-13 Years 9.3 (7.5-11.5)
14-17 Years 55.5 (51.7-59.4) 14-17 Years 45.3 (41.8-48.9)
Socioeconomic status Socioeconomic status
Low 42.0 (35.5-48.8) Low 30.1 (24.5-36.4)
Medium 42.6 (39.0-46.2) Medium 32.2 (29.3-35.2)
High 41.0 (36.8-45.4) High 31.6 (27.9-35.5)
Place of residence   Place of residence   
East German federal states 55.6 (50.7-60.4) East German federal states 43.6 (39.1-48.2)
West German federal states 40.0 (36.7-43.3) West German federal states 29.5 (26.9-32.2)
 *  According to the current STIKO recommendation: defined as two vaccinations if started until the age of 14 years or three vaccinations if started at 15 years or 
older, regardless as to whether the minimum six months between vaccinations has been met
HPV=Human papillomavirus, CI=Confidence interval
 *  According to the current STIKO recommendation: defined as two vaccina-
tions if started until the age of 14 years or three vaccinations if started at  
15 years or older, regardless as to whether the minimum six months between 












KiGGS Wave 1 KiGGS Wave 2
Table 1 
Prevalences of at least one single 
HPV vaccination dose (n=2,958 girls) and 
self-reported complete HPV vaccination series* 
(n=2,916 girls) according to age, socioeconomic 
status and place of residence 
Source: KiGGS Wave 2 (2014-2017)
Figure 1 
Prevalence of self-reported complete 
HPV vaccination series* for 14- to 17-year old 
girls according to age in KiGGS Wave 1 
(n=1,326) and KiGGS Wave 2 (n=1,668) 
Source: KiGGS Wave 1 (2009-2012), 
KiGGS Wave 2 (2014-2017)
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such as the significantly lower frequency of physician con-
sultations compared to the groups of infants and toddlers. 
A good opportunity for counselling on HPV vaccination for 
this age group is the J1 early detection examination for 12- 
to 14-year-old adolescents. However, in spite of great 
regional differences, only 50% of adolescents in Germany 
participate [16]. An analysis of ASHIP data showed that 
12-year-old girls that participated in the J1 examination were 
seven times more likely to have received at least one HPV 
vaccination [12]. This positive association was also clearly 
evident in KiGGS Wave 1 data for the age group of 14- to 
17-year-old girls [10].
HPV vaccination coverage surveyed in KiGGS indicates 
that only about half of all girls or their parents/legal 
guardians, respectively, decide for a vaccination to protect 
them against HPV infections. The preventive potential of 
HPV vaccination against cervical cancer is so far not being 
fully exploited. In addition to the direct, individual protec-
tion, with a sufficiently high vaccination coverage of around 
80% protection through herd immunity can be observed 
[17], also allowing for protection of unimmunized women 
in the community. In the summer of 2018, STIKO extended 
the HPV vaccination recommendation also to 9- to 14-year-
old boys [18]. The additional vaccination of boys will most 
likely lead to an increase of the positive vaccination effects, 
as more young people will be protected directly and indi-
rectly through herd immunity against HPV infections and 
HPV-associated tumors. 
participants in health studies are more aware of their health 
and that their vaccination coverage might differ from the 
general population (selection bias). This is undermined by 
the prevalence of participation in adolescent routine health 
screening examinations (J1 examination), indicating a 
higher level of utilization of health services by girls partic-
ipating in KiGGS. For 15-year-old girls who participated in 
KiGGS Wave 1 (2009 – 2012), the rate was significantly 
higher than the prevalences calculated based on ASHIP 
data [12] for 15-year-old girls (60.1% vs 50.1%). It must 
therefore be assumed that the HPV vaccination coverage 
surveyed in KiGGS Wave 2 overestimates the actual vacci-
nation coverage in German girls. 
In the years following the HPV vaccination recommen-
dation for girls, use and risk profile of HPV vaccination has 
been discussed widely and critically in the general public 
[13], leading to a hesitant or negative attitude towards HPV 
vaccination in parts of the population. KiGGS Wave 1 results 
still reflected those attitudes by showing clear differences 
in HPV vaccination coverage according to socioeconomic 
status [10]. KiGGS Wave 2 no longer shows an association 
between HPV vaccination coverage and socioeconomic 
status. Moreover, in a current survey of the German Fed-
eral Centre for Health Education (BZgA), nearly 80% of 
16- to 20-year-old women considered HPV vaccination as 
‘(particularly) important’ [14]. At the same time, in a Face-
book-based survey among young women on HPV vaccina-
tion, safety concerns were the most common reason given 
for not receiving the vaccination [15]. Besides lack of infor-
mation on the safety profile of the vaccination, another rea-
son for the relatively low vaccination coverage in the age 
group of 9- to 17-year-old girls could be structural issues 
12- to 17-year-old girls 
received their first HPV 
vaccination on average at the 
age of 13 years and nine 
months which is five months 
earlier than in KiGGS Wave 1 
five years ago.
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